Gal Markel

Petah Tiqwa, M, Israel

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 109 publications

CT Body Composition Changes Predict Survival in Immunotherapy-Treated Cancer Patients: A Retrospective Cohort Study.

CT Body Composition Changes Predict Survival in Immunotherapy-Treated Cancer Patients: A Retrospective Cohort Study.

Journal: Cancers

Published: December 30, 2025

Comparative and Critical Analysis of Immune-based Combinations for First-line Treatment of Metastatic Renal Cell Carcinoma.

Comparative and Critical Analysis of Immune-based Combinations for First-line Treatment of Metastatic Renal Cell Carcinoma.

Journal: Clinical genitourinary cancer

Published: December 15, 2025

Anti-4CB1: A Novel Selective HVEM-Blocking Antibody Enhancing T-Cell and Macrophage Immunity Against Solid Tumors.

Anti-4CB1: A Novel Selective HVEM-Blocking Antibody Enhancing T-Cell and Macrophage Immunity Against Solid Tumors.

Journal: Molecular cancer therapeutics

Published: November 27, 2025

PD-1 inhibitor treatment outcomes for cutaneous squamous cell carcinoma in patients over 85: a comparative analysis.

PD-1 inhibitor treatment outcomes for cutaneous squamous cell carcinoma in patients over 85: a comparative analysis.

Journal: The oncologist

Published: October 31, 2025

Vibostolimab coformulated with pembrolizumab versus pembrolizumab alone as adjuvant therapy for high-risk stage IIB-IV melanoma (KEYVIBE-010): a randomised, double-blind, phase 3 study.

Vibostolimab coformulated with pembrolizumab versus pembrolizumab alone as adjuvant therapy for high-risk stage IIB-IV melanoma (KEYVIBE-010): a randomised, double-blind, phase 3 study.

Journal: The Lancet. Oncology

Published: June 30, 2025

Clinical outcomes following PD-1 inhibitor elective discontinuation in cutaneous squamous cell carcinoma: exploring treatment de-escalation.

Clinical outcomes following PD-1 inhibitor elective discontinuation in cutaneous squamous cell carcinoma: exploring treatment de-escalation.

Journal: Cancer immunology, immunotherapy : CII

Published: March 06, 2025

Challenges in Interpreting Survival Metrics in Clinical Trials: The Utility of Restricted Mean Survival Analyses.

Challenges in Interpreting Survival Metrics in Clinical Trials: The Utility of Restricted Mean Survival Analyses.

Journal: International journal of radiation oncology, biology, physics

Published: January 30, 2025

Reanalysis of Urothelial Cancer Chemoimmunotherapy Trials With Differential Censoring.

Reanalysis of Urothelial Cancer Chemoimmunotherapy Trials With Differential Censoring.

Journal: JAMA network open

Published: January 22, 2025

TMED inhibition suppresses cell surface PD-1 expression and overcomes T cell dysfunction.

TMED inhibition suppresses cell surface PD-1 expression and overcomes T cell dysfunction.

Journal: Journal for immunotherapy of cancer

Published: August 09, 2024

Survival outcomes of population-wide colonoscopy screening: reanalysis of the NordICC data.

Survival outcomes of population-wide colonoscopy screening: reanalysis of the NordICC data.

Journal: BMC gastroenterology

Published: July 15, 2024

Assessing the effect of metastasis-directed therapy in oligometastatic disease using the restricted mean survival time.

Assessing the effect of metastasis-directed therapy in oligometastatic disease using the restricted mean survival time.

Journal: British journal of cancer

Published: December 06, 2023

Projecting complete redaction of clinical trial protocols (RAPTURE): redacted cross sectional study.

Projecting complete redaction of clinical trial protocols (RAPTURE): redacted cross sectional study.

Journal: BMJ (Clinical research ed.)

Published: November 07, 2023

Showing 1-12 of 109

Last Updated: 09/26/2026